[ONTX] Onconova Therapeutics, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ONTX
ONTX is in the medium-term down -67% in 2 years and down -87% in 2 years and down -93% in 2 years. In the long-term down -95% in 4 years and up 30069% in 23 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -8.8% | Sales Growth - Q/Q | 0% | P/E | ||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -156.2% | ROE | -487.72% | ROI | ||
| Current Ratio | 3.38 | Quick Ratio | Long Term Debt/Equity | Debt Ratio | 0.92 | ||
| Gross Margin | Operating Margin | -12282.7% | Net Profit Margin | -12279.7% | Dividend Payout Ratio | ||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | -9.85 M | Gross Profit | |||
| Net Profit | -12.34 M | Operating Profit | -12.35 M | Total Assets | 36.71 M | Total Current Assets | 36.35 M |
| Total Current Liabilities | 10.76 M | Total Debt | Total Liabilities | 24.95 M | Total Revenue | 110 K |
Technical Data
| High 52 week | 5.78 | Low 52 week | 0.3 | Last close | 0.3 | Last change | -24.58% |
| RSI | 26.62 | Average true range | 0.06 | Beta | 0.13 | Volume | 18.76 K |
| Simple moving average 20 days | -37.42% | Simple moving average 50 days | -66.09% | Simple moving average 200 days | -88.69% |
Performance Data
| Performance Week | -16.19% | Performance Month | -64.92% | Performance Quart | -86.53% | Performance Half | -90.77% |
| Performance Year | -92.55% | Performance Year-to-date | -85.7% | Volatility daily | 10.4% | Volatility weekly | 23.26% |
| Volatility monthly | 47.67% | Volatility yearly | 165.14% | Relative Volume | 157.7% | Average Volume | 426.28 K |
| New High | New Low |
News
2021-04-01 08:00:00 | Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China
2021-03-29 08:00:00 | Onconova to Present at the Spring 2021 Oncology Investor Conference
2021-03-11 16:05:00 | Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update
2021-03-11 14:30:00 | Onconova Therapeutics, Inc. to Host Earnings Call
2021-03-04 16:15:00 | Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results
2021-03-01 08:00:00 | Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March
2021-02-24 08:00:00 | Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
2021-02-22 09:47:21 | 5 Value Stocks In The Healthcare Sector
2021-02-17 17:51:00 | Why Onconova Therapeutics Stock Soared Today
2021-02-16 16:03:00 | Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option
2021-02-16 08:00:00 | Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference
2021-02-10 22:49:00 | Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
2021-02-10 16:01:00 | Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
2021-02-04 11:54:52 | Return On Capital Employed Overview: Onconova Therapeutics
2021-01-25 09:49:21 | 5 Value Stocks In The Healthcare Sector
2021-01-14 08:00:00 | Onconova Therapeutics, Inc. to Present at NobleCon17 Virtual Event
2021-01-07 09:40:00 | Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering
2020-12-21 08:00:00 | Onconova Therapeutics Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
2020-12-01 10:27:09 | Return On Capital Employed Overview: Onconova Therapeutics
2020-11-23 08:00:00 | Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
2020-11-12 16:05:00 | Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
2020-11-12 14:30:00 | Onconova Therapeutics, Inc. to Host Earnings Call
2020-11-05 08:00:00 | Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
2020-10-13 08:00:00 | Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
2020-10-05 09:44:52 | 5 Value Stocks To Watch In The Healthcare Sector
2020-09-21 10:08:46 | Looking Into Onconova Therapeutics's Return On Capital Employed
2020-09-21 08:00:00 | Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
2020-09-09 08:00:00 | Onconova Therapeutics Announces Participation at Upcoming Virtual Events
2020-08-31 08:41:12 | Overview Of Value Stocks In The Healthcare Sector
2020-08-31 08:00:00 | Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors
2020-08-26 18:42:22 | After an Unfortunate Surprise, Can Onconova Bounce Back? Analyst Weighs In
2020-08-25 10:06:02 | Onconova's Cancer Study Fails to Meet Endpoint, Shares Down
2020-08-24 11:15:20 | Return On Capital Employed Overview: Onconova Therapeutics
2020-08-24 07:30:00 | Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial
2020-08-17 11:46:52 | 5 Value Stocks To Watch In The Healthcare Sector
2020-08-12 16:37:08 | Onconova Therapeutics: Q2 Earnings Insights
2020-08-12 16:05:00 | Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
2020-08-07 08:00:00 | Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
2020-08-04 08:00:00 | Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement
2020-08-03 11:52:03 | Onconova ONTX to Report Q2 Earnings: What's in the Offing?
2020-07-29 13:30:00 | Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
2020-07-27 08:00:00 | Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
2020-07-23 08:00:00 | Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
2020-07-07 08:00:10 | Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
2020-06-23 10:43:02 | Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate
2020-06-23 08:00:10 | Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
2020-06-22 08:00:10 | Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
2020-06-12 08:00:10 | Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association EHA
2020-06-08 08:00:10 | Onconova Therapeutics Announces Presentation at BIO Digital 2020
2020-05-28 09:44:06 | 3 “Strong Buy” Penny Stocks That Offer Massive Potential Gains